The Claim
In patients with atherosclerosis or diabetes and LDL cholesterol levels of at least 90 mg/dL who have not experienced a prior myocardial infarction or stroke, evolocumab 140 mg administered every two weeks demonstrates a safety profile comparable to placebo, with no significant difference in the overall incidence of adverse events over a median follow-up period of 4.6 years.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a drug called evolocumab every two weeks is just as safe as taking a fake pill (placebo) for people with certain heart risks — there’s no real difference in side effects after nearly 5 years.
See the scientific wording
Evolocumab 140 mg administered every 2 weeks has a safety profile comparable to placebo in patients with atherosclerosis or diabetes and LDL-C ≥90 mg/dL who have not had a prior myocardial infarction or stroke, with no significant difference in the overall incidence of adverse events over a median of 4.6 years of follow-up
What the research says
1 studyStudy: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
The study found that people taking evolocumab every two weeks had about the same number of side effects as those taking a placebo over nearly 5 years, so it supports the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.